Dendritic Cell Cancer Vaccines

Description

Global Dendritic Cell Cancer Vaccines Market to Reach US$1.7 Billion by 2030

The global market for Dendritic Cell Cancer Vaccines estimated at US$806.1 Million in the year 2024, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 13.0% over the analysis period 2024-2030. Sipuleucel-T Vaccines, one of the segments analyzed in the report, is expected to record a 14.7% CAGR and reach US$987.7 Million by the end of the analysis period. Growth in the CreaVax Vaccines segment is estimated at 12.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$211.9 Million While China is Forecast to Grow at 12.1% CAGR

The Dendritic Cell Cancer Vaccines market in the U.S. is estimated at US$211.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$259.6 Million by the year 2030 trailing a CAGR of 12.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.2% and 11.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.3% CAGR.

Global Dendritic Cell Cancer Vaccines Market - Key Trends & Drivers Summarized

Why Are Dendritic Cell Cancer Vaccines Gaining Attention in Immunotherapy?

Dendritic cell (DC) cancer vaccines have emerged as a promising frontier in oncology, leveraging the body’s immune system to combat malignancies. Unlike traditional cancer treatments such as chemotherapy and radiation, which often have severe side effects, DC vaccines offer a personalized and targeted approach to cancer therapy. These vaccines work by priming dendritic cells with tumor antigens, enabling them to activate T-cells for an enhanced immune response against cancer cells. The growing recognition of immunotherapy as a viable cancer treatment has propelled research and investment in dendritic cell-based vaccines. The increasing incidence of cancers such as melanoma, prostate, lung, and glioblastoma has further fueled interest in personalized vaccine strategies. Additionally, breakthroughs in cancer genomics and molecular biology are improving vaccine efficacy, offering new hope for patients with aggressive and treatment-resistant cancers. As research progresses, DC vaccines are being evaluated for their potential to complement existing immunotherapies, such as checkpoint inhibitors and CAR-T cell therapy, creating a more comprehensive and durable cancer treatment landscape.

How Are Advancements in Biotechnology Enhancing DC Vaccine Development?

The development of dendritic cell cancer vaccines has been significantly enhanced by advancements in biotechnology, including gene editing, synthetic biology, and nanotechnology. CRISPR-based gene editing has enabled researchers to engineer dendritic cells with enhanced antigen presentation capabilities, improving their effectiveness in stimulating the immune system. Additionally, the use of messenger RNA (mRNA) technology-popularized by COVID-19 vaccines-is being explored for developing next-generation DC vaccines with more efficient tumor antigen loading. Innovations in nanocarriers and lipid nanoparticles have also improved vaccine delivery, enhancing the bioavailability and stability of therapeutic dendritic cells. Furthermore, artificial intelligence (AI) and big data analytics are being employed to identify novel cancer antigens, optimizing the personalization of DC vaccines for different tumor types. As these technological advancements continue to evolve, they are expected to drive the development of more effective and scalable dendritic cell cancer vaccine platforms.

What Are the Regulatory and Market Challenges Facing DC Vaccines?

Despite their potential, dendritic cell cancer vaccines face several regulatory and commercial challenges. The high cost and complexity of personalized vaccine manufacturing remain significant hurdles, as each vaccine must be tailored to an individual patient’s tumor profile. Additionally, the stringent regulatory approval process for cellular immunotherapies requires extensive clinical trials and long-term efficacy data, delaying market entry. The lack of standardized protocols for dendritic cell preparation and antigen loading has also led to variability in vaccine effectiveness across different patient groups. However, regulatory agencies such as the FDA and EMA are increasingly supporting immunotherapy research, providing fast-track designations for promising DC vaccine candidates. Additionally, biotech companies and research institutions are forming strategic partnerships to scale up production and reduce costs. With continued investment in automation and bioprocessing technologies, the challenges surrounding DC vaccine commercialization are expected to be gradually mitigated.

What Are the Key Growth Drivers in the Dendritic Cell Cancer Vaccines Market?

The growth in the dendritic cell cancer vaccines market is driven by several factors, including the rising global cancer burden and increasing demand for personalized immunotherapy solutions. Advances in biotechnology, particularly in gene editing, mRNA technology, and nanomedicine, have significantly enhanced the efficacy and scalability of DC vaccines. The growing adoption of combination immunotherapies, integrating DC vaccines with checkpoint inhibitors and monoclonal antibodies, has further expanded treatment possibilities. Regulatory support for cellular immunotherapies, including expedited approval pathways, has accelerated clinical trials and market entry for new DC vaccine candidates. Additionally, increased funding from government agencies, research institutions, and biotech firms has driven innovation and commercialization efforts. As the field of cancer immunotherapy continues to evolve, dendritic cell cancer vaccines are expected to play a critical role in the future of oncology, offering a targeted and durable solution for patients with hard-to-treat cancers.

SCOPE OF STUDY:

The report analyzes the Dendritic Cell Cancer Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Sipuleucel-T Vaccines, CreaVax Vaccines, Other Products); End-Use (Adults Vaccines End-Use, Pediatrics Vaccines End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

Argos Therapeutics, Inc.
Asgard Therapeutics
BioNTech SE
Candel Therapeutics
CureVac N.V.
Dendreon Pharmaceuticals LLC
Diakonos Oncology
Genexine, Inc.
GlaxoSmithKline plc (GSK)
ImmunoCellular Therapeutics, Ltd.
Immunomic Therapeutics, Inc.
Medigene AG
Mestag Therapeutics
Mill Creek Life Sciences
Moderna, Inc.
Northwest Biotherapeutics
PDC*line Pharma
Scancell Holdings plc
SOTIO Biotech
TransImmune AG

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Product Code: MCP30414

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Influencer Market Insights
- Tariff Impact on Global Supply Chain Patterns
- Dendritic Cell Cancer Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Advances in Immuno-Oncology Throw the Spotlight on Dendritic Cell Cancer Vaccines as a Personalized Therapy Frontier
- Rising Global Cancer Burden Spurs Interest in Novel, Targeted Treatment Modalities
- Breakthroughs in Antigen Presentation and T-Cell Activation Strengthen the Case for Dendritic Cell Therapies
- Clinical Trial Momentum and Pipeline Expansion Accelerate Innovation in DC Vaccine Platforms
- Favorable Regulatory Pathways for Cell-Based Immunotherapies Support Fast-Track Approvals
- Increased Collaboration Between Academia and Biotech Fuels R&D in Personalized Cancer Vaccines
- Integration of Genomic and Neoantigen Profiling Enhances Precision in Dendritic Cell Vaccine Design
- Growing Acceptance of Autologous and Allogeneic Cell Therapies Expands Use in Solid Tumors and Hematologic Cancers
- Combination Therapies with Checkpoint Inhibitors Drive Synergistic Treatment Strategies
- Cryopreservation and Manufacturing Advances Improve Scalability and Patient Access
- Reimbursement Progress and Orphan Drug Incentives Encourage Market Entry for Niche Indications
- Patient Demand for Personalized Medicine Drives Interest in Tumor-Antigen-Targeted DC Vaccines
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Dendritic Cell Cancer Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 3: World 6-Year Perspective for Dendritic Cell Cancer Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
- TABLE 4: World Recent Past, Current & Future Analysis for Sipuleucel-T Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 5: World 6-Year Perspective for Sipuleucel-T Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 6: World Recent Past, Current & Future Analysis for CreaVax Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 7: World 6-Year Perspective for CreaVax Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 9: World 6-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 10: World Recent Past, Current & Future Analysis for Adults Vaccines End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 11: World 6-Year Perspective for Adults Vaccines End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 12: World Recent Past, Current & Future Analysis for Pediatrics Vaccines End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 13: World 6-Year Perspective for Pediatrics Vaccines End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES
- Dendritic Cell Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 14: USA Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 15: USA 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
- TABLE 16: USA Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 17: USA 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030
CANADA
- TABLE 18: Canada Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 19: Canada 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
- TABLE 20: Canada Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 21: Canada 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030
JAPAN
- Dendritic Cell Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 22: Japan Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 23: Japan 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
- TABLE 24: Japan Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 25: Japan 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030
CHINA
- Dendritic Cell Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 26: China Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 27: China 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
- TABLE 28: China Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 29: China 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030
EUROPE
- Dendritic Cell Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 30: Europe Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 31: Europe 6-Year Perspective for Dendritic Cell Cancer Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
- TABLE 32: Europe Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 33: Europe 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
- TABLE 34: Europe Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 35: Europe 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030
FRANCE
- Dendritic Cell Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 36: France Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 37: France 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
- TABLE 38: France Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 39: France 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030
GERMANY
- Dendritic Cell Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 40: Germany Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 41: Germany 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
- TABLE 42: Germany Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 43: Germany 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030
ITALY
- TABLE 44: Italy Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 45: Italy 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
- TABLE 46: Italy Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 47: Italy 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030
UNITED KINGDOM
- Dendritic Cell Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 48: UK Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 49: UK 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
- TABLE 50: UK Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 51: UK 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030
REST OF EUROPE
- TABLE 52: Rest of Europe Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 53: Rest of Europe 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
- TABLE 54: Rest of Europe Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 55: Rest of Europe 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030
ASIA-PACIFIC
- Dendritic Cell Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 57: Asia-Pacific 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
- TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 59: Asia-Pacific 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030
REST OF WORLD
- TABLE 60: Rest of World Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 61: Rest of World 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
- TABLE 62: Rest of World Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 63: Rest of World 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030